vs

Side-by-side financial comparison of Aeva Technologies, Inc. (AEVA) and C4 Therapeutics, Inc. (CCCC). Click either name above to swap in a different company.

C4 Therapeutics, Inc. is the larger business by last-quarter revenue ($11.0M vs $5.6M, roughly 2.0× Aeva Technologies, Inc.). C4 Therapeutics, Inc. runs the higher net margin — -186.0% vs -450.3%, a 264.4% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 108.5%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 63.3%).

Aeva Technologies, Inc. is a publicly traded American corporation specializing in sensing hardware and perception software, including LiDAR, headquartered in Mountain View, California. Aeva makes sensing and perception tools for vehicular automation, metrology, and industrial automation.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

AEVA vs CCCC — Head-to-Head

Bigger by revenue
CCCC
CCCC
2.0× larger
CCCC
$11.0M
$5.6M
AEVA
Growing faster (revenue YoY)
CCCC
CCCC
+4.3% gap
CCCC
112.8%
108.5%
AEVA
Higher net margin
CCCC
CCCC
264.4% more per $
CCCC
-186.0%
-450.3%
AEVA
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
63.3%
AEVA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AEVA
AEVA
CCCC
CCCC
Revenue
$5.6M
$11.0M
Net Profit
$-25.3M
$-20.5M
Gross Margin
23.5%
Operating Margin
-517.6%
-210.1%
Net Margin
-450.3%
-186.0%
Revenue YoY
108.5%
112.8%
Net Profit YoY
30.0%
40.7%
EPS (diluted)
$2.10
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AEVA
AEVA
CCCC
CCCC
Q4 25
$5.6M
$11.0M
Q3 25
$3.6M
$11.2M
Q2 25
$5.5M
$6.5M
Q1 25
$3.4M
$7.2M
Q4 24
$2.7M
$5.2M
Q3 24
$2.3M
$15.4M
Q2 24
$2.0M
$12.0M
Q1 24
$2.1M
$3.0M
Net Profit
AEVA
AEVA
CCCC
CCCC
Q4 25
$-25.3M
$-20.5M
Q3 25
$107.5M
$-32.2M
Q2 25
$-192.7M
$-26.0M
Q1 25
$-34.9M
$-26.3M
Q4 24
$-36.1M
$-34.6M
Q3 24
$-37.4M
$-24.7M
Q2 24
$-43.4M
$-17.7M
Q1 24
$-35.3M
$-28.4M
Gross Margin
AEVA
AEVA
CCCC
CCCC
Q4 25
23.5%
Q3 25
12.0%
Q2 25
-49.4%
Q1 25
9.2%
Q4 24
-30.7%
Q3 24
-32.0%
Q2 24
-42.1%
Q1 24
-66.1%
Operating Margin
AEVA
AEVA
CCCC
CCCC
Q4 25
-517.6%
-210.1%
Q3 25
-926.5%
-306.4%
Q2 25
-633.7%
-441.0%
Q1 25
-903.1%
-402.9%
Q4 24
-1270.0%
-728.4%
Q3 24
-1683.4%
-183.9%
Q2 24
-2431.1%
-178.6%
Q1 24
-1772.4%
-1060.2%
Net Margin
AEVA
AEVA
CCCC
CCCC
Q4 25
-450.3%
-186.0%
Q3 25
3003.5%
-286.4%
Q2 25
-3497.4%
-402.6%
Q1 25
-1035.2%
-363.7%
Q4 24
-1340.7%
-667.8%
Q3 24
-1662.0%
-160.6%
Q2 24
-2156.7%
-147.6%
Q1 24
-1676.6%
-933.2%
EPS (diluted)
AEVA
AEVA
CCCC
CCCC
Q4 25
$2.10
$-0.09
Q3 25
$-0.52
$-0.44
Q2 25
$-3.49
$-0.37
Q1 25
$-0.64
$-0.37
Q4 24
$-0.66
$-0.50
Q3 24
$-0.70
$-0.35
Q2 24
$-0.82
$-0.26
Q1 24
$-0.67
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AEVA
AEVA
CCCC
CCCC
Cash + ST InvestmentsLiquidity on hand
$121.9M
$74.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$13.2M
$256.6M
Total Assets
$179.7M
$359.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AEVA
AEVA
CCCC
CCCC
Q4 25
$121.9M
$74.6M
Q3 25
$48.9M
$58.8M
Q2 25
$49.8M
$78.2M
Q1 25
$81.0M
$51.3M
Q4 24
$112.0M
$55.5M
Q3 24
$134.8M
$59.6M
Q2 24
$160.2M
$73.1M
Q1 24
$189.3M
$89.7M
Stockholders' Equity
AEVA
AEVA
CCCC
CCCC
Q4 25
$13.2M
$256.6M
Q3 25
$33.2M
$154.4M
Q2 25
$-118.2M
$174.1M
Q1 25
$68.8M
$195.1M
Q4 24
$99.4M
$216.0M
Q3 24
$129.3M
$242.7M
Q2 24
$160.0M
$247.1M
Q1 24
$198.2M
$258.3M
Total Assets
AEVA
AEVA
CCCC
CCCC
Q4 25
$179.7M
$359.1M
Q3 25
$92.8M
$265.5M
Q2 25
$91.1M
$296.5M
Q1 25
$114.5M
$319.5M
Q4 24
$147.5M
$349.6M
Q3 24
$169.1M
$376.1M
Q2 24
$198.1M
$381.1M
Q1 24
$224.8M
$398.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AEVA
AEVA
CCCC
CCCC
Operating Cash FlowLast quarter
$-22.1M
$-22.1M
Free Cash FlowOCF − Capex
$-23.7M
FCF MarginFCF / Revenue
-420.9%
Capex IntensityCapex / Revenue
26.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-119.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AEVA
AEVA
CCCC
CCCC
Q4 25
$-22.1M
$-22.1M
Q3 25
$-32.3M
$-31.2M
Q2 25
$-29.8M
$-12.1M
Q1 25
$-30.8M
$-33.3M
Q4 24
$-20.9M
$-17.9M
Q3 24
$-25.9M
$-24.1M
Q2 24
$-29.2M
$-5.0M
Q1 24
$-31.0M
$-18.1M
Free Cash Flow
AEVA
AEVA
CCCC
CCCC
Q4 25
$-23.7M
Q3 25
$-33.6M
$-31.6M
Q2 25
$-31.2M
Q1 25
$-31.3M
Q4 24
$-23.0M
$-17.9M
Q3 24
$-26.4M
$-24.1M
Q2 24
$-29.9M
$-5.2M
Q1 24
$-32.6M
FCF Margin
AEVA
AEVA
CCCC
CCCC
Q4 25
-420.9%
Q3 25
-938.4%
-281.5%
Q2 25
-566.0%
Q1 25
-927.9%
Q4 24
-854.5%
-346.5%
Q3 24
-1174.7%
-157.2%
Q2 24
-1488.3%
-43.1%
Q1 24
-1547.7%
Capex Intensity
AEVA
AEVA
CCCC
CCCC
Q4 25
26.9%
Q3 25
35.6%
3.7%
Q2 25
24.8%
Q1 25
13.6%
Q4 24
79.3%
0.1%
Q3 24
24.1%
0.1%
Q2 24
38.7%
1.6%
Q1 24
78.2%
0.0%
Cash Conversion
AEVA
AEVA
CCCC
CCCC
Q4 25
Q3 25
-0.30×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons